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Why discuss EP? - the Evidence
• Does it make a difference to treat in early phase?
• If so what should be the optimal treatment?
• Does it make a difference to treat in a specialized way? Does a 
program make any difference?
• What is the state of psychopathology in early stages?
-------------------------------------------------------------------------------------------
• What is the natural outcome in EI
• What is appropriate Pharmacological therapy
• How and why to Integrate psychosocial and pharmacological 
therapies
• What is adequate Maintenance treatment
• What are the pertinent issues in Long term perspective 
The philosophy is to identify earliest and 
treat to ensure full remission and function.
What Is Early Psychosis?
• the first episode of psychosis involves poor 
performance in multiple cognitive domains, 
including affective psychoses.
• A meta-analysis of 12 functional MRI studies 
revealed decreased dorsolateral prefrontal 
cortex activation in first-episode psychosis.
• Neuropathologic studies have found decreased 
somal size and dendritic spine density in 
pyramidal neurons of the dorsolateral prefrontal 
cortex
When Does the First Episode of Psychosis 
Occur?
• A long-standing question relates to whether the 
neuropathology of psychosis begins in 
adolescence or long before.
• A study from the Pittsburgh High Risk Study, 
which included 76 high-risk offspring of parents 
with schizophrenia, reported gray matter 
reductions in the high-risk group and even 
greater reductions among those with 
schizotypy.
• Furthermore, scores on attention and executive 
functioning (measured with the Continuous Performance 
Task and the Wisconsin Cart Sorting Test) declined in 
the high-risk group during the premorbid phase whereas 
these cognitive scores increased in the control group.
• Other groups have found gray matter losses during the 
premorbid and prodromal phases.
• In summary, the "when" of first-episode psychosis can 
be described as a sequential, cascading process from 
childhood to early adolescence to later adolescence, 
with cognitive and imaging findings present before the 
onset of psychosis
When Does the First Episode of Psychosis 
Occur?
Why Does Early Psychosis Occur?
• The "why" of first-episode psychosis is also an 
area of intensive research. 
• Both genetic and environmental factors are 
important to the etiology of the illness. 
• Genes of interest to schizophrenia researchers 
appear to relate to the glutamatergic system (for 
example, the "disrupted in schizophrenia-1" 
[DISC-1] gene or the regulator of G-protein 
signaling 4 [RGS4] gene).
Does it make a difference 
to treat in early  phase
Benefits of Early Treatment
• More rapid effect
• Lower dose required
• Increased effects on positive symptoms
• Fewer residual symptoms
• Fewer deficit symptoms
• Fewer future relapses
• Better social integration
Models of early intervention service
Yung AR, Organ BA, Harris MG. Aust N Z J Psychiatry. 2003 Aug;37(4):429-36.
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Canada’s Early Intervention Services
Ontario:
•PEPP, London 
•FEPP, Toronto 
•Psychotic Disorders U., Hamilton
•Ottawa FEPP
•KPP&TP, Kingston
Alberta:
•EPT&PP, Calgary (930,000)
British Columbia:
•EP Initiative of British Columbia
•EPIVMHC,Victoria
•Vancouver
•EPIP, White Rock
Quebec:
•Levis
•Montreal
•Quebec City
Nova Scotia:
•NSEPP
•Halifax -
Saskatchewan:
•EIPP, Saskatoon
Key figures:
•Jean Addington
•Bob Zipursky
•Ashok Malla
•Lili Kopala
Newfoundland
•N&L EPP
Early intervention Program
• Essentially a political agenda 
• Welfare
• Targets prevention
• Initially has high investment
• But in long run it will cut mental 
health spending or at least will
• Optimize the usage of funds
• Expected to minimize spending on 
chronic patients 
Early Intervention is a
Public health initiative 
• SMI utilizes >90% of Budget globally
• Bipolar Disorder and schizophrenia are 
main SMIs
• Bipolar Disorder < schizophrenia : 
epidemiologically, possibly because of 
better outcome of affective disorders.
• In schizophrenia we need to find avenues 
of innovation.
• That has been ‘Early intervention’
Schizophrenia-Economic Cost 
• Direct cost in USA 19 billion and indirect 
46 b.
• Cost of schizophrenia care was 837 M 
Pounds in UK ; 94% being spent on SMI 
and inpatients care
• Active psychosis was third most disabling 
condition ahead of paraplegia and 
blindness. Point prevalence 0.4%
• GBD of schizophrenia was 1.1% of total 
DALY and 2.8% of YLD.
• Even after recovery residual symptoms 
are disabling and lead to poor QOL.
Schizophrenia- unmet needs 
• 30-50% patients attempt suicide 
sometimes in life time ,
• 10% patients die due to suicide
• A schizophrenia patient has life span    
10-20 years lesser. 
• Not more than 10% patients have access 
to treatment
• Not more than 10% receive care
• Not more than 10% emergencies receive 
treatment
Schizophrenia- Early Intervention 
• A disease of late-childhood and 
early adolescence.
• Investment for early treatment is 
far more lesser than expenditure 
on delayed ( increased 
DUP) treatment.
• Thus EI is  a sensible and 
manageable economic agenda.
• What is EP
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Cannabis and Early Psychosis
• It is widely known that patients with schizophrenia, 
including first-episode patients, have much higher rates 
of cannabis use compared with their counterparts in the 
general population.
• Recent epidemiologic research has discovered that 
cannabis is likely a component cause of psychosis, 
• meaning that cannabis use in combination with genetic 
and/or environmental factors exerts a causal influence 
on the onset of psychosis in individuals at risk.
Cannabis may reduce the age of onset of 
psychosis.
• Institute of Psychiatry at the Maudsley, London, UK, --
preliminary data from the Genetics and Psychosis 
(GAP) study
• With a goal to recruit 1000 first-episode patients, the 
research project currently has 278 participants (72% 
male; mean age of 25 years; 51.3% black/African 
English, 37.7% white). 
• 56% had used cannabis and 19% had used other 
drugs. 
• There were no significant differences in substance 
abuse prevalence rates across ethnic groups. 
• Preliminary data from this ongoing study suggest that 
cannabis may reduce the age of onset of psychosis. 
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Post-FEP: the Critical Phase of Psychosis
• Individual is vulnerable to negative influence because of 
a combination of factors:-
• Coping up with return of insight and depression
• A realization of having developed a mental illness/brain 
disorder
• Question about future functioning
• Ideas of faith, trust and mistrust
• ‘why me’
• Why medication, 
• Negative EE
• Attitude of family members
• persisting psychotic symptoms in remission 
Duration of Untreated Psychosis
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Neurobiology of EP 
• Brain structure and 
function alteration , present 
early and pre-date onset of 
symptoms,
• Changes in frontal and 
temporal lobes.
• Functional and 
neurochemical brain 
abnormalities are seen in 
premorbid and early 
phase.
• Some can be trait like.
• others might progress.
• # Heredity is the best established risk factor;
• # Premorbid neurocognitive alterations clearly exist;
• # Prodromal symptoms often precede psychosis;
• # Onset of psychosis is typically in late adolescence; 
and
• # Cognitive deficits are central to the illness
An Overview of the Neurobiology of Early 
Psychosis
Keshavan MS, Pittsburgh & Detroit
Cognitive impairment in 
schizophrenia: prevalence
• 85% of stable outpatients with minimal 
psychotic symptoms show significant 
cognitive impairment
• In contrast, specific delusions and 
hallucinations are present in as few  as 
25 to 40% of patients
Cognitive dysfunction is a lasting feature
of schizophrenia
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Cognitive deficits are the best predictors of 
functional outcome
Atypicals and cognition: comparison of 
effects  Bilder et al Am J Psychiatry 2002
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Prediction of Psychosis
Yung et al 1998 British Journal of Psychiatry
0
5
10
15
20
25
0 1 2 3 4 5 6
Months of assessment
Number not
psychotic
40% made 
transition at six
months, 50% at
one year 
Prevention of psychosis
McGorry et al 2002 Archives of General Psychiatry
0%
5%
10%
15%
20%
25%
30%
35%
40%
6 12
Needs based Tx Specific interventions
Months
% making 
transition
to psychosis
Predicting onset of psychosis:PACE
What features predict onset of first-episode 
within an ultra-high risk group?
• Duration of symptoms more than 900 days
• GAF  less than 51
• BPRS total score greater than 15
• BPRS-Psychotic scale more than 2
• SANS attention score more than 1
• HDRS more than 18
• Normal left hippocampal volume
• Cannabis dependence
• Maternal age more than 30 years
Prodromal features in first-episode 
psychosis most commonly described 
in first-episode studies
• Reduced concentration, attention
• Reduced drive, motivation, anergia
• Depressed mood
• Sleep disturbance
• Anxiety
• Social withdrawal
• Suspiciousness
• Deterioration in role functioning
• Irritability
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AN  “ EARLY” DEVELOPMENT THEORY:  
impaired neural migration  in schizophrenia?
Normal Schizophrenia
Akbarian 1993
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Aim of management in FEP
EI Services in many countries developed based on 
the evidence
Germany,Australia, UK,Canada, USA, 
Sweden,Denmark 
• To  reduce the time between onset of psychotic 
symptom and effective treatment
• To accelerate remission through  effective 
biological and psychosocial interventions.
• To reduce individual’s adverse reaction to the 
experience of psychosis and to maximize social 
and work functioning
• To prevent relapse and treatment resistance
Principles of  best practice management
• A strategy for early detection and 
assessment of frank psychosis.
• A specific focus on therapeutic 
engagement
• A comprehensive assessment
• An embracing of diagnostic uncertainty
• Treatment in least restrictive setting using 
low-dose medication
Recommendation for pharmacotherapy  of 
first episode psychosis
• An antipsychotic free observation period
• A low threshold for use of atypical antipsychotic 
medications
• The use of low dose antipsychotic plus 
benzodiazepines.
• The aim of remission
• Early assessment of treatment resistance
• Maintenance of medication for at least 1-2 years 
in non-affective psychosis( except in case with 
short  DUP)
Early Intervention 
• Focus on psychological adjustment and 
maintenance of social roles
• Focus of entire family
• Prevention of relapse and resistance to 
treatment
• Now the practices of the  EI services are 
gearing up to Prodrome of First episode 
psychosis
First-episode schizophrenia versus chronic 
schizophrenia treated with risperidone (1)
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Response rate in FES
How much antipsychotic
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Olanzapine vs. Haloperidol 
First-episode Psychosis
Should AATPD be used
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First episode psychosis: Relapses
Antipsychotics for how long?
Quetiapine in FEP
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Improvement in Symptoms and cognitive tests
Aripiprazole in Teen-Schizophrenia
• Six week, double-blind, randomized placebo-controlled trial 
was conducted at 101 centers in 13 countries, A total of 
302 adolescents, ranging in age from 13 to 17 (mean age 
15.5),
• DSM-IV diagnosis of schizophrenia, and a Positive and 
Negative Syndrome Scale total score of 70 or greater.
• More than 85% of the patients completed the study. 
• The mean baseline Positive and Negative Syndrome score 
was 94.5.
• After one week on the full drug dose, patients in the 30-mg 
group had a significant improvement compared with 
placebo in total PANSS score (-10.42 compared with -
7.2,LOCF, P<0.05).
• Both the 10-mg and 30-mg doses showed significant 
differences
San Diego; APA, May,2007
Predictor of response
• Diagnosis 
• Baseline disorganization
• NS
• Akathesia
• Dystonia
• Psychosis activation by 
methylphenidate
• Baseline motor function
• N-P test
• Severe hallucination and 
delusions
• Level of depression
• Higher premorbid 
functioning
• More acute onset
• Shorter duration of illness
• Lower baseline PS NS
• Nondefecit state status
• Absence of parkinsons 
sign during APD Tx
Not related to response Related to response
Limitations of pharmacological 
treatment in FEP
• Remission of psychotic symptoms only in
50% individuals within first 3 months;
75% within first 6 months  and
Up to 80% in 1Year
• Benefits are tampered by
• Side effects
• Medication adherence , with 6-12 Mths ,33-50% 
• Persistent psychosis up to 20%
• Significant depression and anxiety 
secondary to traumatic experience 
of psychosis,– up to 50%
• Poor functional recovery (79% of 75% remitted 
were non-functional; Tohen et al 2000, 
Biol.Psych, Harvard FE Project)
• Impairment of General social Functioning, QOL, 
& Occupational Functioning despite clinical 
recovery. This prevails up to 5  years  after 
onset even with optimal pharmacological 
treatment
Limitations of pharmacological treatment in 
FEP-2
Psychosocial Intervention
• Pharmacotherapy alone is not enough.
• Means facilitating recovery from an initial episode of 
psychosis and reducing the long-term disability 
associated with schizophrenia.
• Research is growing
• Treatment guidelines for FEP based on clinical 
experience not research includes : , therapeutic 
engagement,targeting psychological and social 
adjustment, developing an active relapse prevention 
plan, and identifying barriers to treatment,
Issues  for psychosocial therapy
“breaking-the-barriers”
• Goals
• Short term
• Long term
• Factors causing 
disengagement
• Factors Interfering 
continuation &
• Compliance
• Factors interfering 
with personal growth 
